HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mann, W. A. Articles by Beisiegel, U. Search for Related Content PubMed PubMed Citation Articles by Mann, W. A. Articles by Beisiegel, U. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 36, 517-525, Copyright © 1995 by Lipid Research, Inc.

ARTICLES

Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia

WA Mann, N Meyer, W Weber, S Meyer, H Greten and U Beisiegel
Medizinische Kern- und Poliklinik, Universitatskrankenhaus Eppendorf, Hamburg, Germany.

The LDL receptor-independent binding of human apolipoprotein E isoforms and rare apoE mutations were studied on LDL receptor-deficient human fibroblasts using chemical cross-linking and cell binding studies. The cross-linking experiments demonstrated that all apoE variants bind to the low density lipoprotein receptor-related protein, a potential receptor for remnant lipoproteins. In cell binding studies, the effect of the apoE variants on binding of beta-VLDL was investigated. Addition of normal apoE-3 to the binding assay resulted in a 12-fold increase of beta-VLDL particle binding, whereas this effect was reduced in the clinically defective variants: apoE-2, (Arg158-->Cys), 24.4% of apoE-3; apoE-1, (Gly127-->Asp, Arg158-->Cys), 49.2% of apoE-3; apoE-1(Lys146-- >Glu), 18.2% of apoE-3. Heparin binding studies with the same variants showed a parallel reduction in proteoglycan binding (apoE-2(158), 58.2% of apoE-3; apoE-1(127,158), 37.9%; apoE-1(146), 20.6%). We conclude that LDL receptor-independent mechanisms contribute to remnant clearance. The functionally dominant mutation apoE-1(146) was most defective in heparin binding studies in vitro. In cell binding studies, apoE-1(146) did mediate lipoprotein binding only 18% compared to apoE- 3. This indicates the important role of the apoE interaction with proteoglycans in vivo and could explain the development of type III hyperlipoproteinemia in patients with such apoE variants.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. Saito, P. Dhanasekaran, D. Nguyen, F. Baldwin, K. H. Weisgraber, S. Wehrli, M. C. Phillips, and S. Lund-Katz Characterization of the Heparin Binding Sites in Human Apolipoprotein E J. Biol. Chem., April 18, 2003; 278(17): 14782 - 14787. [Abstract] [Full Text] [PDF]

				K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]

				C. P. Libeu, S. Lund-Katz, M. C. Phillips, S. Wehrli, M. J. Hernaiz, I. Capila, R. J. Linhardt, R. L. Raffai, Y. M. Newhouse, F. Zhou, et al. New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E J. Biol. Chem., October 12, 2001; 276(42): 39138 - 39144. [Abstract] [Full Text] [PDF]

				M. M. HOFFMANN, H. SCHARNAGL, E. PANAGIOTOU, W. T. BANGHARD, H. WIELAND, and W. MÄRZ Diminished LDL Receptor and High Heparin Binding of Apolipoprotein E2 Sendai Associated with Lipoprotein Glomerulopathy J. Am. Soc. Nephrol., March 1, 2001; 12(3): 524 - 530. [Abstract] [Full Text]

				F. de Beer, K. W. van Dijk, M. C. Jong, L. C. van Vark, A. van der Zee, M. H. Hofker, F. J. Fallaux, R. C. Hoeben, A. H. M. Smelt, and L. M. Havekes Apolipoprotein E2 (Lys146->Gln) Causes Hypertriglyceridemia due to an Apolipoprotein E Variant-Specific Inhibition of Lipolysis of Very Low Density Lipoproteins-Triglycerides Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1800 - 1806. [Abstract] [Full Text] [PDF]

				R. W. Mahley, Y. Huang, and S. C. Rall , Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J. Lipid Res., November 1, 1999; 40(11): 1933 - 1949. [Abstract] [Full Text]

				F. de Beer, W. L. Hendriks, L. C. van Vark, S. W.A. Kamerling, K. W. van Dijk, M. H. Hofker, A. H.M. Smelt, and L. M. Havekes Binding of ß-VLDL to Heparan Sulfate Proteoglycans Requires Lipoprotein Lipase, Whereas ApoE Only Modulates Binding Affinity Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 633 - 637. [Abstract] [Full Text] [PDF]

				W. März, M. M. Hoffmann, H. Scharnagl, E. Fisher, M. Chen, M. Nauck, G. Feussner, and H. Wieland Apolipoprotein E2 (Arg136 -> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia J. Lipid Res., March 1, 1998; 39(3): 658 - 669. [Abstract] [Full Text]

				W. J.S. de Villiers, D. R. van der Westhuyzen, G. A. Coetzee, H. E. Henderson, and A. D. Marais The Apolipoprotein E2(Arg145Cys) Mutation Causes Autosomal Dominant Type III Hyperlipoproteinemia With Incomplete Penetrance Arterioscler. Thromb. Vasc. Biol., May 1, 1997; 17(5): 865 - 872. [Abstract] [Full Text]

				I. V. Fuki, R. V. Iozzo, and K. J. Williams Perlecan Heparan Sulfate Proteoglycan. A NOVEL RECEPTOR THAT MEDIATES A DISTINCT PATHWAY FOR LIGAND CATABOLISM J. Biol. Chem., August 11, 2000; 275(33): 25742 - 25750. [Abstract] [Full Text] [PDF]